Heiko Pohl1, Silvia Benemei2, David Garcia-Azorin3, Joanna Dixon4, Elizabeth Huzzey5, Michel D Ferrari6. 1. Department of Neurology, University Hospital Zurich, Zurich, Switzerland. 2. Careggi University Hospital, Florence, Italy. 3. Department of Neurology, Hospital Clínico Universitario de Valladolid, Valladolid, Spain. 4. MEDIAN Kinzigtal-Klinik, Bad Soden-Salmünster, Germany. 5. Watford Osteopaths, London, United Kingdom. 6. Department of Neurology, Leiden University Medical Centre, Leiden, the Netherlands.
Abstract
OBJECTIVE: We propose a new outcome measure to assess the efficacy of migraine treatments translating the approach of the Global Burden of Disease studies from a societal to an individual level: Instead of calculating "years lived with disability", we suggest estimating "time lost due to an attack". METHODS: Time lost due to an attack is calculated by multiplying the duration and the degree of impaired functioning during an attack. RESULTS: Time lost due to an attack, different from other outcome measures, does not just focus on the short-term analgesic effects of treatments, but rather on the improvement of all migraine symptoms and restoration of functioning, also considering therapy-related impairment. Importantly, time lost due to an attack measures the entire time patients are not functioning normally, from onset to complete resolution. CONCLUSIONS: Time lost due to an attack represents a new paradigm to assess migraine burden in single patients for a patient-centered evaluation of both acute and prophylactic treatments.
OBJECTIVE: We propose a new outcome measure to assess the efficacy of migraine treatments translating the approach of the Global Burden of Disease studies from a societal to an individual level: Instead of calculating "years lived with disability", we suggest estimating "time lost due to an attack". METHODS: Time lost due to an attack is calculated by multiplying the duration and the degree of impaired functioning during an attack. RESULTS: Time lost due to an attack, different from other outcome measures, does not just focus on the short-term analgesic effects of treatments, but rather on the improvement of all migraine symptoms and restoration of functioning, also considering therapy-related impairment. Importantly, time lost due to an attack measures the entire time patients are not functioning normally, from onset to complete resolution. CONCLUSIONS: Time lost due to an attack represents a new paradigm to assess migraine burden in single patients for a patient-centered evaluation of both acute and prophylactic treatments.
Authors: Matthew J Khayata; Samantha Farley; J Kelly Davis; Christoph P Hornik; Bryce B Reeve; Aruna Rikhi; Amy A Gelfand; Christina L Szperka; Shirley Kessel; Tara Pezzuto; Alex Hammett; Monica E Lemmon Journal: Headache Date: 2022-05-06 Impact factor: 5.311
Authors: Heiko Pohl; Anne-Catherine Streit; Maria S Neumeier; Gabriele S Merki-Feld; Willibald Ruch; Andreas R Gantenbein Journal: Womens Health Rep (New Rochelle) Date: 2022-02-02